forum

MARKSANS Share Price Discussion

Marksans Pharma Ltd.
Sector: Pharmaceuticals and health care
... Read more
MARKSANS Share Price *
15.55 -0.25 (-1.58%)
* (quote may be delayed)

MARKSANS Discussion Forum

Like
reply
Reply
share
Share
Like
reply
Reply
share
Share

Marksans Pharma reported better than street estimates of Q3 results. Company reported Q3 net profit Rs251.3mn (up 44% YoY), EBITDA margin 14.5% vs 13.2% (QoQ) and sales Rs2.48bn (up 14% YoY)
Like
reply
Reply
share
Share
  • MARKSANS - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization1,295.43
    Enterprise Value1,361.58
    Price to Earnings104.22
    Price to Book Value3.02
    Return on Capital Employed0.05
    Return on Equity0.03
    Face Value1
    Dividend YieldNA
  • MARKSANS Share Price - Technicals

    keyboard_arrow_down
    MARKSANS - 52 Week High₹38.3
    MARKSANS - 52 Week Low₹11.4
  • MARKSANS - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    11-Jun-18CentrumHold31
    22-Feb-18CentrumBuy55
    30-Sep-16Dynamic LevelsBuy70
    29-Sep-16CentrumBuy60
    View all MARKSANS - Share Targets - Broker Reports
  • MARKSANS Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 1615.416.215.0515.55
    Sep 1315.916.0515.2515.8
    Sep 1216.616.815.6515.9
    Sep 1115.916.815.716.55
    Sep 914.416.1514.315.65
  • MARKSANS Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹14.72
    30 Day Moving Average₹15.33
    50 Day Moving Average₹16.35
    100 Day Moving Average₹19.36
    200 Day Moving Average₹22.84
  • MARKSANS - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue294.66215.840.37
    Operating Profit36.4524.190.51
    Profit Before Tax16.6512.580.32
    Net Income12.4312.230.02
  • MARKSANS - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds428.97430.03-0
    Total Liabilities127.28128.45-0.01
    Total Assets556.25547.480.02
  • MARKSANS - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity23.17-18.67-2.24
    Cash from Investing Activity-7.52-7.8-0.04
    Cash from Financing Activity-17.525.9-1.68
    Net Cash Flow-1.85-0.572.25
  • MARKSANS - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.020.02
    Return on Equity0.030.03
    Return on Capital Employed0.050.03
  • MARKSANS - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.27
    3 Year CAGR Growth in Operating Profit-0.69
    3 Year CAGR Growth in EBIDTA-0.69
    3 Year CAGR Growth in Net Income-0.81
    3 Yr CAGR Growth - Diluted EPS-0.82
  • MARKSANS - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.53
    5 Year CAGR Growth in Operating Profit-0.18
    5 Year CAGR Growth in EBIDTA-0.24
    5 Year CAGR Growth in Net Income-0.69
    3 Yr CAGR Growth - Diluted EPS-0.71
  • MARKSANS Share Price - Recent News

    keyboard_arrow_down
    NewsBot
    Jun 6 10:08 PM
    NewsBot
    Jun 6 9:38 PM
    NewsBot
    Mar 7 7:52 PM
    NewsBot
    Nov 17 10:47 PM
  • MARKSANS - Related Communities

    keyboard_arrow_down
    Wanbury Ltd. Sector: Pharmaceuticals ...
    Piramal Phytocare Ltd. Sector: Pharma...
    Parabolic Drugs Ltd. Sector: Pharmace...
    Orchid Pharma Ltd. Sector: Pharmaceut...
    Biofil Chemicals & Pharmaceuticals Lt...
    Wockhardt Ltd. Sector: Pharmaceutical...
    Vivimed Labs Ltd. Sector: Pharmaceuti...
    Venus Remedies Ltd. Sector: Pharmaceu...
    Unichem Laboratories Ltd. Sector: Pha...
    TTK Healthcare Ltd. Sector: Pharmaceu...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.